A new immunotherapy company has been launched in the UK, based on science conducted by Caetano Reis e Sousa and colleagues at the Francis Crick Institute in London. Adendra Therapeutics Ltd will research candidate drugs for the treatment of solid cancers and T cell-based autoimmune disorders by exploiting dendritic cell biology.
